Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other 1Gastrointestinal 1

Conditions

Obesity 298Mucositis 116Neoplasms 108Breast Neoplasms 87Overweight 80Sexual Dysfunction, Physiological 74Polycystic Ovary Syndrome 71Dyspnea 48Motor Activity 46Constipation 45Head and Neck Neoplasms 42Weight Loss 36Prostatic Neoplasms 32Pain 29Stomatitis 26Endometrial Neoplasms 23Opioid-Induced Constipation 22Multiple Endocrine Neoplasia Type 1 20Diabetes Mellitus 20Lung Neoplasms 18Colorectal Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Sexual Dysfunctions, Psychological 15Depression 15Cardiovascular Diseases 15Anxiety Disorders 15Sedentary Behavior 13Insulin Resistance 13Infertility 13Cancer-related Fatigue 13

Interventions

isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Macroglossia × Other × Clear all
NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

SWOG Cancer Research Network

Phase 2 Completed
43 enrolled 23 charts
GastrointestinalOtherPlasma cell

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

Data powered by HemOnc (CC BY 4.0) Colophon âš¡